Marker in Prostate Cancer Fails to Predict Response to PARP Inhibition

Video

This video examines clinical and genomics data from the NCI 9012 trial, which studied abiraterone combined with a PARP inhibitor in patients with metastatic castration-resistant prostate cancer.

In this video, Maha H. Hussain, MD, of the Lurie Cancer Center in Chicago, discusses clinical and genomics data from the NCI 9012 trial, which studied abiraterone and prednisone with or without the PARP inhibitor veliparib in patients with metastatic castration-resistant prostate cancer (mCRPC).

Hussain reports that ETS fusion–positive tumors did not predict response to treatment, but also that the design of the trial allowed investigators to discover a surprise finding among patients with DNA repair gene–deficient tumors.

The study results were presented (abstract 5001) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago.

Recent Videos
A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Related Content